The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Inclusion Criteria: * Patients with newly diagnosed stage I-IV breast cancer (tumor size * 2cm in imaging examinations) who are scheduled to start systemic therapy. * Patients must have histological diagnosis of invasive breast cancer. * Extent of disease will be determined by physical examination and conventional radiological studies. * Must be age 18 or older. * ECOG performance status 0-2. * Patients with history of prior malignancies must be disease-free for at least 5 years of study entry. * Normal hematological function: WBC \> 3000/ul, absolute neutrophil count \> 1500/ul, platelets \> 100,000/ul, and Hgb \> 10 gms (transfusion to achieve Hgb \> 10 gms is acceptable). * Serum total bilirubin \< 1.5 mg/dl and SGPT \< 1.5 X normal. * Adequate kidney function (creatinine \< 1.5 mg/dL). Exclusion Criteria: * Patients who received previous chemotherapy for the newly diagnosed breast cancer. * No evidence of primary breast lesion (e.g. T0, Tx). * Pregnant women or sexually active women of childbearing potential who are not practicing adequate contraception are excluded. * Patients with myocardial infarction within 6 months of study entry; unstable angina pectoris; uncontrolled congestive heart failure; uncontrolled arrhythmia are excluded. * Patients with history of hypersensitivity/allergy to Chitosan/Chitin related shellfish foods.